Fig. 6

TAGLN2 expression in patient tissues and cancer-associated fibroblasts. (A) TAGLN2 expression in normal human tissues assessed using IHC. (B) Representative images show the expression of TAGLN2 in cancer cells and the stroma portion of BTC surgical tissues. (C) The DFS and OS by Kaplan–Meier analysis comparing low- and high-TAGLN2 IHC index in cancer and stroma, respectively. (D) IF findings in BTC tissue show overexpression of TAGLN2 in the stroma of BTC tissue, and its location coincided with α-SMA expression. (E) TAGLN2 expressed in the CAFs from BTC assessed using IF. Typical morphology of fibroblast in bright fields, expression of α-SMA and FAP, and non-expression of the epithelial marker as CK-7 in the IF study are shown